Riluzole for Cognitive Dysfunction in Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This is a phase II single-arm, Phase 2a, randomized, double-blinded, placebo-controlled pilot clinical trial determining efficacy of riluzole in preventing cognitive dysfunction in subjects with cancer, who are receiving chemotherapy.
Who Is on the Research Team?
Alexandre Chan, PharmD, MPH
Principal Investigator
Chao Family Comprehensive Cancer Center
Are You a Good Fit for This Trial?
Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either riluzole or placebo twice daily for up to 6 months
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Riluzole
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Placebo Group
Study participants randomized to this arm will take 50 mg of riluzole twice daily (every 12 hours) for up to 6 months
Study participants randomized to this arm will take a placebo, that matches the appearance of 50 mg capsule of riluzole, twice daily (every 12 hours) for up to 6 months
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of California, Irvine
Lead Sponsor
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.